At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 92 enrolled
Drug / intervention
Teriparatide +1 moredrug
Likely dose
Teriparatide 20 µgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Comparison of the Effects of Teriparatide With Those of Risedronate on Lumbar Spine vBMD in Glucocorticoid-Induced Osteoporosis in Men
In Brief
A Phase 3 clinical trial evaluating Teriparatide and Risedronate for Osteoporosis. Completed, enrolled 92 participants across 13 sites in 4 countries.
Detailed Summary
The objective of this study is to test the hypothesis that teriparatide is superior to the active comparator in the change from baseline to 18 months of lumbar spine volumetric trabecular bone mineral density (BMD) in males with glucocorticoid-induced osteoporosis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoporosis
CountriesGermany, Greece, Italy, Spain
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2007
First PostedJul 2007
Primary CompletionOct 2010
TodayJul 2026
First PostedJul 18, 2007
Enrollment StartJul 1, 2007
Primary CompletionOct 1, 2010
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 19.0 years ago
Interventions
Teriparatidedrug
20 µg/day sc for 18 months
Risedronatedrug
35 mg/week po for 18 months